Matrix Metalloproteinases (MMPs),Neutrophil Gelatinase-associated Lipocalin (NGAL) Tissue and Plasma Levels and Aneurysms
NCT ID: NCT02145533
Last Updated: 2014-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
307 participants
OBSERVATIONAL
2010-01-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In a multicenter, open label, parallel groups, prospective study, patients with aneurysmal disease were divided into two groups: Group I (with ruptured aneurysm) and Group II (with non-ruptured aneurysm). Healthy volunteer patients were also enrolled and represented the control group (Group III).
The investigators enrolled 307 patients (Group I: 107, Group II: 200) with arterial aneurysm: 49 popliteal, 31 common femoral, 2 superficial femoral, 29 common iliac artery, 3 common carotid and 193 abdominal aorta. Finally, 11 healthy volunteer patients (9 males and 2 females, age range 40-70 year-old, median 56) were enrolled in Group III.
Elisa test and Western blot analysis revealed greater levels of immunoreactive MMP-9 and NGAL in all patients with ruptured aneurysms, both central and peripheral aneurysms, and in the aneurismal vessels.
These results provide important advances in the understanding of the natural history of arterial aneurysms. MMPs and NGAL play a role in development of arterial aneurysms and they may represent molecular markers for the prevention of aneurysmal rupture
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Statins in Artery Aneurysms
NCT03061487
The Biomechanical Study of Diseased Human Carotid, Femoral and Abdominal Aortic Tissue
NCT05802706
Predicting Rupture of AAA by Anatomic and Hemodynamic Markers
NCT02463760
Multicentre Trial Of Serum Levels Of MMP-9 As A Biomarker Of Endoleak
NCT01965717
Multidimensional Evaluation of Patients With Ruptured or Unruptured Cerebral Aneurysm Undergoing Endovascular or Surgical Treatment
NCT05713825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
patient with ruptured aneurysms
No interventions assigned to this group
Group II
patients with non-ruptured aneurysms
No interventions assigned to this group
Group III
Healthy volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hepatic failure
* Infectious or autoimmune diseases
* Patients requiring endovascular treatment.
35 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Catanzaro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luca Gallelli
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefano de Franciscis, M.D.
Role: STUDY_CHAIR
University Magna Graecia of Catanzaro
Raffaele Serra
Role: PRINCIPAL_INVESTIGATOR
University Magna Graecia of Catanzaro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Catanzaro
Catanzaro, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SURVAS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.